TABLE 1.
Antimicrobial (CLSI intermediate breakpoint)b | MIC of delafloxacin against (no. of isolates): |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
M. abscessus subsp. abscessus (16) | M. abscessus subsp. massiliense (5) | M. chelonae (11) | M. immunogenum (5) | M. fortuitumf (13) | M. fortuitum (CIPS) (9) | M. fortuitum (CIPR) (4) | M. porcinum (7) | M. senegalense (7) | M. mucogenicum group (5) | M. goodii (1) | |
DEL (NA)d | |||||||||||
MIC range | ≥16 | 4 to >16 | ≥16 | 8 to >16 | 0.001 to >16 | 0.001–0.5 | 2 to >16 | 0.12–1 | 0.25–1 | 0.03–0.12 | 0.06 |
MIC50 | >16 | >16 | >16 | >16 | 0.25 | 0.12 | 2 | 0.25 | 0.5 | 0.12 | NA |
MIC90 | >16 | >16 | >16 | >16 | 2 | 0.5 | NA | 1 | 1 | 0.12 | NA |
CIP (2) | |||||||||||
MIC range | ≥4 | 0.5 to >4 | 0.5 to >4 | ≤0.12–4 | ≤0.12 to >4 | 0.12–1 | 4 to >4 | ≤0.12–0.5 | 0.25–0.5 | ≤0.12–2 | ≤0.12 |
MIC50 | 4 | 4 | 1 | 2 | ≤0.12 | ≤0.12 | >4 | ≤0.12 | 0.5 | 0.25 | NA |
MIC90 | >4 | >4 | 4 | 4 | >4 | 1 | NA | 0.5 | 0.5 | 2 | NA |
MXF (2) | |||||||||||
MIC range | 4 to >16 | 2 to >16 | 1 to >8 | 1 to >8 | ≤0.06–8 | ≤0.06–0.25 | ≤0.06–8 | ≤0.06–0.25 | ≤0.06–0.12 | 0.25–0.5 | ≤0.06 |
MIC50 | 8 | 8 | 2 | 1 | 0.12 | ≤0.06 | 0.5 | ≤0.06 | 0.12 | 0.25 | NA |
MIC90 | 16 | >16 | 4 | 4 | 1 | 0.25 | NA | 0.25 | 0.12 | 0.5 | NA |
AMK (32) | |||||||||||
MIC range | 4 to >64 | 8–16 | ≤2–64 | 4–16 | ≤2–4 | ≤2 | ≤2–4 | ≤2 | ≤2 | ≤2 | ≤2 |
MIC50 | 8 | 8 | 8 | 8 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | ≤2 | NA |
MIC90 | 16 | 16 | 32 | 16 | ≤2 | ≤2 | NA | ≤2 | ≤2 | ≤2 | NA |
FOX (32–64) | |||||||||||
MIC range | 32–64 | 16–32 | >64 | >64 | ≤16–64 | ≤16–64 | 32–64 | ≤16–32 | ≤16 | ≤16 | 32 |
MIC50 | 32 | 32 | >64 | >64 | 32 | 32 | 64 | ≤16 | ≤16 | ≤16 | NA |
MIC90 | 64 | 32 | >64 | >64 | 64 | 64 | NA | 32 | ≤16 | ≤16 | NA |
SXT (NA)c | |||||||||||
MIC rangee | 2/38 to >4/76 | 2/38–4/76 | 1/19–4/76 | ≤0.5/9.5 to >4/76 | ≤0.5/9.5–2/38 | ≤0.5/9.5–2/38 | ≤0.5/9.5–1/19 | ≤0.5/9.5–2/38 | ≤0.5/9.5–2/38 | ≤0.5/9.5 | ≤0.5/9.5 |
MIC50 | 4/76 | 4/76 | 2/38 | 4/76 | 0.5–9.5 | 0.5–9.5 | ≤0.5/9.5 | 1/19 | 1/19 | ≤0.5/9.5 | NA |
MIC90 | >4/76 | 4/76 | 4/76 | >4/76 | 2/38 | 2/38 | NA | 2/38 | 2/38 | ≤0.5/9.5 | NA |
LZD (16) | |||||||||||
MIC range | 2–32 | 1–16 | 2–16 | 2–16 | ≤1-8 | ≤1–4 | 2-8 | ≤1–2 | ≤1–2 | ≤1 | ≤1 |
MIC50 | 16 | 8 | 8 | 4 | 2 | 2 | 2 | ≤1 | 2 | ≤1 | NA |
MIC90 | 32 | 16 | 8 | 16 | 4 | 4 | NA | 2 | 4 | ≤1 | NA |
IPM (8–16) | |||||||||||
MIC range | 4 to >32 | 8 to >32 | 4–32 | 8–32 | ≤2–8 | ≤2–8 | ≤2–8 | ≤2 to >8 | ≤2–4 | ≤2–8 | ≤2 |
MIC50 | 8 | 16 | 16 | 16 | ≤2 | ≤2 | ≤2 | 4 | 4 | 4 | NA |
MIC90 | 32 | >32 | 16 | 32 | 8 | 8 | NA | 8 | 4 | 8 | NA |
DOX (2–4) | |||||||||||
MIC range | >8 | 2 to >8 | ≤0.12 to >8 | 4 to >8 | ≤0.12 to >8 | ≤0.12 to >8 | 0.25 to >8 | 2–8 | ≤0.12 | ≤0.12 to >8 | ≤0.12 |
MIC50 | >8 | >8 | >8 | >8 | 4 | ≤0.12 | 8 | 4 | ≤0.12 | ≤0.12 | NA |
MIC90 | >8 | >8 | >8 | >8 | >8 | >8 | NA | 8 | ≤0.12 | >8 | NA |
MIN (2–4) | |||||||||||
MIC range | >8 | >8 | ≤1 to >8 | >8 | ≤1 to >8 | ≤1 to >8 | ≤1 to >8 | 4 to >8 | ≤1 | ≤1 to >8 | ≤1 |
MIC50 | >8 | >8 | >8 | >8 | >8 | ≤1 | ≤1 | 4 | ≤1 | ≤1 | NA |
MIC90 | >8 | >8 | >8 | >8 | >8 | >8 | NA | >8 | ≤1 | >8 | NA |
TGC (NA)d | |||||||||||
MIC range | 0.06–0.5 | 0.06–0.25 | ≤0.03–0.12 | ≤0.03–0.12 | ≤0.03–0.06 | ≤0.03–0.06 | ≤0.03 | ≤0.03 | ≤0.03 | ≤0.03–0.25 | ≤0.03 |
MIC50 | 0.12 | 0.12 | 0.06 | 0.12 | ≤0.03 | ≤0.03 | ≤0.03 | ≤0.03 | ≤0.03 | 0.06 | NA |
MIC90 | 0.25 | 0.25 | 0.12 | 0.12 | 0.06 | 0.06 | NA | ≤0.03 | ≤0.03 | 0.25 | NA |
CLR (4) | |||||||||||
MIC range | ≤2 to >16 | ≤2 to >16 | ≤2 | ≤2 | ≥16 | ≥16 | ≥16 | ≥16 | 1-≤2 | ≤2 | 8 |
MIC50 | ≥16 | ≤2 | ≤2 | ≤2 | ≥16 | >16 | ≥16 | >16 | ≤2 | ≤2 | NA |
MIC90 | ≥16 | ≥16g | ≤2 | ≤2 | ≥16 | >16 | NA | >16 | ≤2 | ≤2 | NA |
TOB (4) | |||||||||||
MIC range | NA | NA | ≤2 | 4 to >8 | NA | NA | NA | NA | NA | NA | NA |
MIC50 | NA | NA | ≤2 | >8 | NA | NA | NA | NA | NA | NA | NA |
MIC90 | NA | NA | ≤2 | >8 | NA | NA | NA | NA | NA | NA | NA |
NA = not applicable.
DEL, delafloxacin; AMK, amikacin; FOX, cefoxitin; SXT, trimethoprim sulfamethoxazole; LZD, linezolid; CIP, ciprofloxacin; IPM, imipenem; MXF, moxifloxacin; DOX, doxycycline; MIN, minocycline; TGC, tigecycline; CLR, clarithromycin; TOB, tobramycin.
There are no intermediate breakpoints for SXT; the resistance breakpoint is >64 μg/ml.
The CLSI has not addressed breakpoints for tigecycline (TGC) or delafloxacin (DEL).
MIC90 values were not calculated for groups with <5 isolates.
Four isolates were known to be quinolone resistant.
Isolate was mutationally macrolide resistant.